文献速递外周动脉疾病

长段股浅动脉病变支架置入后的结局比较

Outcomes after Endovascular Stent Placement for Long-Segment Superficial Femoral Artery Lesions.
PubMed 文献 · Ann Vasc Surg · 2020-09-03

一项回顾性队列研究分析226例长段(≥15 cm)股浅动脉病变患者,比较裸金属支架、覆膜支架和药物洗脱支架的长期结局。校正混杂因素后,药物洗脱支架较覆膜支架在 primary-assisted 和 secondary patency 上更优,且覆膜支架闭塞后急性肢体缺血风险显著高于裸金属支架。

要点

  • 药物洗脱支架较覆膜支架有更优的 primary-assisted 和 secondary patency。
  • 覆膜支架闭塞后表现为急性肢体缺血的风险是裸金属支架的27倍。
  • 三种支架的 amputation-free survival 和全因死亡率无显著差异。

核心结论

  • 对于长段股浅动脉病变,药物洗脱支架在长期随访中与更好的 primary-assisted 和 secondary patency 相关。
  • 支架闭塞时,覆膜支架与急性肢体缺血风险增加相关。

研究设计与样本

  • 回顾性队列研究,纳入症状性股浅动脉病变长度至少15 cm且成功接受血管内支架(裸金属支架、覆膜支架或药物洗脱支架)的患者。
  • 共分析226例手术(裸金属支架95例[42%],覆膜支架74例[33%],药物洗脱支架57例[25%])。

主要发现

  • 未校正的 primary patency 在裸金属支架12、24、48个月分别为57%、47%、44%,覆膜支架为62%、49%、42%,药物洗脱支架为81%、66%、53%(log-rank P = 0.044)。
  • 校正模型后,三种支架的 primary patency 无显著差异。
  • 与覆膜支架相比,药物洗脱支架的 primary-assisted patency(patency loss 的 HR 0.35,P = 0.008)和 secondary patency(HR 0.32,P = 0.011)更优。
  • 随访期间支架闭塞发生率:裸金属支架38例(40%)、覆膜支架42例(57%)、药物洗脱支架11例(19%)(P < 0.001)。
  • 闭塞病例中急性肢体缺血发生率:裸金属支架2例(5%)、覆膜支架14例(33%)、药物洗脱支架1例(9%)(P = 0.010)。

关键数值与推荐

  • 股浅动脉病变长度中位数:裸金属支架28 cm(IQR 20-30),覆膜支架26 cm(IQR 20-30),药物洗脱支架20 cm(IQR 16-25)(P = 0.002)。
  • 三种支架的 amputation-free survival 和全因死亡率无显著差异。

临床怎么用

  • 长段股浅动脉病变选择支架时,药物洗脱支架可能提供更好的长期通畅性。
  • 使用覆膜支架时需警惕闭塞后急性肢体缺血风险,应加强随访和患者教育。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular intervention is commonly pursued as first-line management of symptomatic, long-segment superficial femoral artery (SFA) disease. The relative effectiveness and comparative long-term outcomes among bare metal stents (BMS), covered stents (CS), and drug-eluting stents (DES) for long-segment SFA lesions remain uncertain. METHODS: A retrospective cohort study identified patients with symptomatic SFA lesions measuring at least 15 cm in length who successfully received an endovascular stent (BMS, CS, or DES). The outcomes were patency, patient presentation upon stent occlusion, amputation-free survival (AFS), and all-cause mortality. Proportional hazards regressions and a multinomial logistic regression model were used to control for significant confounders. RESULTS: A total of 226 procedures were analyzed (BMS: 95 [42%]; CS: 74 [33%]; DES: 57 [25%]). There were no significant differences among the 3 stent types with respect to age, prevalence of either diabetes or end-stage renal disease, or smoking history. The median length of the SFA lesion varied across the cohorts (BMS: 28 cm [interquartile range, IQR 20-30]; CS: 26 cm [IQR 20-30]; DES: 20 cm [IQR 16-25]; P = 0.002). The unadjusted primary patency of BMS at 12, 24, and 48 month following index stent placement was 57%, 47%, and 44%, respectively. This is compared to 62%, 49%, and 42% for CS, and 81%, 66%, and 53% for DES, respectively (log-rank P = 0.044). In adjusted models, however, there were no significant differences in primary patency among the stent types. Compared to CS however, DES was associated with improved primary-assisted patency (hazard ratio [HR] for patency loss: 0.35, P = 0.008) and secondary patency (HR: 0.32, P = 0.011). Across the entire follow-up period, stent occlusions occurred in 38 (40%) BMS cases, 42 (57%) CS, and 11 (19%) DES (P < 0.001). Of these, acute limb ischemia (ALI) occurred in 2 (5%) BMS cases, 14 (33%) CS, and 1 (9%) DES (P = 0.010). After adjustment, the relative risk of presenting with ALI as opposed to claudication was 27 times greater among patients re-presenting with occluded CS compared to BMS (P = 0.020). There were no significant differences in AFS or all-cause mortality across the 3 cohorts. CONCLUSIONS: For long-segment SFA lesions, DES is associated with improved primary-assisted and secondary patency over long-term follow-up. In the event of stent occlusion, CS is associated with an increased risk of ALI.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Zamani N, Sharath SE, Browder RC, et al. Outcomes after Endovascular Stent Placement for Long-Segment Superficial Femoral Artery Lesions. Ann Vasc Surg. 2020. PMID: 32891746. doi:10.1016/j.avsg.2020.08.124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。